An Overview of Gut Microbiome Studies in Inflammatory Bowel Disease
DOI:
https://doi.org/10.54097/ne1tvd70Keywords:
Gut microbiome; IBD; Dybiosys; Ulcerative Colitis (UC) and Crohn's Disease (CD); Short-chain fatty acids (SCFAs).Abstract
Inflammatory Bowel Disease (IBD) is a complex disorder marked by ongoing inflammation in the gastrointestinal tract. Its intricate connection with the gut's microbial makeup is a significant aspect of its pathology. This detailed investigation delves into the interaction between IBD and gut microbiota, underscoring the crucial role of microbial imbalance in the development of this condition. A thorough comparative examination of the gut microbiota in individuals with and without IBD reveals notable differences. Special attention is given to Short-Chain Fatty Acids (SCFAs) for their influence on intestinal barrier function and immune regulation. The study also assesses the efficacy of microbial intervention strategies like probiotics, prebiotics, Fecal Microbiota Transplantation (FMT), and butyrate supplementation. These findings illuminate the potential of microbiome-focused treatments in reshaping gut flora, pointing to a new direction in IBD management. The paper concludes by proposing a holistic treatment approach that integrates dietary changes with novel therapeutic methods. This research significantly advances our understanding of the gut microbiome's function in IBD, offering novel insights and avenues for more effective management and treatment strategies.
Downloads
References
Kaplan, G.G., Windsor, J.W. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 18, 56–66 (2021). https://doi.org/10.1038/s41575-020-00360-x
Qingdong Guan, "A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease", Journal of Immunology Research, vol. 2019, Article ID 7247238, 16 pages, 2019. https://doi.org/10.1155/2019/7247238
Pittayanon, R., Lau, J.T., Leontiadis, G.I., Yuan, Y., Surette, M., Moayyedi, P., et al. "Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review." Gastroenterology, volume 158, issue 4, pages 930-946.E1, March 2020. Published: December 05, 2019. DOI: https://doi.org/10.1053/j.gastro.2019.11.294
Yuan, S., Wang, K.-S., Meng, H., Hou, X.-T., Xue, J.-C., Liu, B.-H., Cheng, W.-W., Li, J., Zhang, H.-M., Nan, J.-X., Zhang, Q.-G. "The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy." Biomedicine & Pharmacotherapy, Volume 165, September 2023, Article 114893. https://doi.org/10.1016/j.biopha.2023.114893
Dixit K, Chaudhari D, Dhotre D, Shouche Y, Saroj S. Restoration of dysbiotic human gut microbiome for homeostasis. Life Sciences. 2021; 278:119622. https://doi.org/10.1016/j.lfs.2021.119622
Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: a narrative review. European Journal of Clinical Nutrition. 2022; 76:489-501. https://doi.org/10.1038/s41430-021-00991-6
Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, Vatanen T, Hall AB, Mallick H, McIver LJ, Sauk JS, Wilson RG, Stevens BW, Scott JM, Pierce K, Deik AA, Bullock K, Imhann F, Porter JA, Zhernakova A, Fu J, Weersma RK, Wijmenga C, Clish CB, Vlamakis H, Xavier RJ, Huttenhower C. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nature Microbiology. 2019;4(2):293-305. https://doi.org/10.1038/s41564-018-0306-4
Shen Y-H, Zhu H, Zhou L, Zheng Y-Q, Xiang Y, Xie Y, Liu Z-Q, Peng C-Y, Wang L, Zhao X-Q, Zhang Q-Q. In inflammatory bowel disease and extraintestinal manifestations: What role does microbiome play? Engineered Regeneration. 2023; 4:337-348. https://doi.org/10.1016/j.engreg.2023.03.004
Coqueiro AY, Raizel R, Bonvini A, Tirapegui J, Rogero MM. Probiotics for inflammatory bowel diseases: a promising adjuvant treatment. International Journal of Food Sciences and Nutrition. 2019;70(1):20-29. https://doi.org/10.1080/09637486.2018.1471733
Chen D, Chen G, Chen C, Zeng X, Ye H. Prebiotics effects in vitro of polysaccharides from tea flowers on gut microbiota of healthy persons and patients with inflammatory bowel disease. Int J Biol Macromol. 2020 May 3; 158:968-976. doi: 10.1016/j.ijbiomac.2020.04.248.
Wu R, Xiong R, Li Y, Chen J, Yan R. Gut microbiome, metabolome, host immunity associated with inflammatory bowel disease and intervention of fecal microbiota transplantation. Journal of Autoimmunity. [In Press, Corrected Proof]. https://doi.org/10.1016/j.jaut.2023.102362
Imdad A, Pandit NG, Zaman M, Minkoff NZ, Tanner-Smith EE, Gomez-Duarte OG, Acra S, Nicholson MR. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews. 2023, Issue 4. Art. No.: CD012774. DOI: 10.1002/14651858.CD012774.pub3.
Fang H, Fu L, Wang J. Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioMed Research International. 2018; Article ID 8941340. https://doi.org/10.1155/2018/8941340
Zhuang X, Li T, Li M, Huang S, Qiu Y, Feng R, Zhang S, Chen M, Xiong L, Zeng Z. Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2019;25(11):1751-1763. https://doi.org/10.1093/ibd/izz188
Kostic AD, Xavier RJ, Gevers D. The Microbiome in Inflammatory Bowel Diseases: Current Status and the Future Ahead. Gastroenterology. 2014 May;146(6):1489-1499. doi: 10.1053/j.gastro.2014.02.009. Published in final edited form as available in PMC 2015 May 01.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
